solver.press

Adaptive LLM-driven zeroth-order optimization schedules can dynamically adjust mutation rates in mRNA sequence design evolutionary algorithms.

Computer ScienceMar 12, 2026Evaluation Score: 73%

Adversarial Debate Score

67% survival rate under critique

Expert panel critique

Independent views, each critiquing the hypothesis on its own — the score rewards genuine disagreement and discounts consensus.

ChatGPT: It’s falsifiable (compare evolutionary mRNA design performance with LLM-adapted vs static mutation schedules), and AdaEvolve plausibly supports the “LLM-driven adaptive schedule” idea, but the cited papers don’t directly connect to mRNA sequence design or mutation-rate control specifically, leavi...
Claude: The hypothesis is falsifiable and receives moderate support from AdaEvolve, which directly addresses adaptive LLM-driven zeroth-order optimization with dynamic scheduling, but the specific application to mRNA sequence design mutation rates is not evidenced in any of the provided papers, making th...
Gemini: The hypothesis is highly falsifiable and strongly supported by the "Ada

Supporting Research Papers

Literature Assessment

📖 Literature-assessed (LLM)· literature_meta

An LLM's reading of the literature — not computational verification.

Adaptive LLMs may enhance mutation rate adjustments in mRNA design.

Method: literature_meta · Result: inconclusive

Formal Verification

Z3 logical consistency:⚠️ Unverified

Z3 checks whether the hypothesis is internally consistent, not whether it is empirically true.

Experimental Validation Package

This discovery has a Claude-generated validation package with a full experimental design.

Precise Hypothesis

An LLM acting as a meta-controller, which observes the state of an evolutionary/genetic algorithm (population fitness distribution, diversity metrics, generation index, plateau length) and outputs a mutation-rate schedule (and optionally crossover/selection-pressure parameters) at each generation, will produce mRNA sequence design outcomes — measured by predicted stability (e.g., ΔG of secondary structure), codon adaptation index (CAI), predicted translation efficiency, and/or in-silico expression proxy score — that are statistically superior (≥10% improvement in final best-fitness at fixed compute budget, or ≥30% reduction in generations-to-target-fitness) compared to (a) fixed mutation-rate GA, (b) standard adaptive heuristics (1/5-success rule, simulated-annealing-style decay), and (c) CMA-ES self-adaptation, across a defined benchmark suite of mRNA design tasks.

Disproof criteria:
  • No statistically significant improvement (p≥0.05, paired Wilcoxon signed-rank across ≥30 independent runs) in final fitness or generations-to-convergence versus best classical adaptive baseline (1/5-rule or CMA-ES) on ≥3 of 5 benchmark tasks.
  • Improvement is present but disappears when LLM is replaced by a simple learned bandit/linear controller with equivalent state input (i.e., "LLM" component adds no value beyond a much cheaper adaptive controller) — this would falsify the "LLM-specific" claim while leaving "adaptive control" claim intact.
  • Wall-clock or dollar-cost-normalized performance is worse than fixed-schedule GA once LLM inference cost is included.
  • Gains do not generalize beyond the exact benchmark/prompt template used (fail on held-out mRNA targets or held-out organism codon tables).

Spine & Adversarial Read

  • highDecades of evolution-strategy literature (1/5-success rule, CMA-ES step-size adaptation) already solves adaptive mutation-rate control efficiently and cheaply; an LLM call (50-500ms, nonzero $ cost) is a strictly worse mechanism unless it captures information the classical controllers cannot (e.g., semantic understanding of sequence/biological constraints) — this EVP does not yet establish what specific information channel the LLM exploits that a bandit cannot.
    Ablation A (linear/logistic bandit with identical state features) is designed exactly to isolate this; if bandit matches LLM, the EVP's own failure criteria call this correctly as a negative result. This is acknowledged as the central risk, not resolved in advance.
  • mediumWhy these specific benchmarks and fitness oracles (ViennaRNA/CAI) rather than wet-lab-validated expression data or a broader established mRNA design benchmark suite? Method choice appears convenience-driven (fast, free, in-silico) rather than justified against the therapeutic-relevance target of the claim.
    Partial justification given: in-silico oracles are necessary for statistical power (n=30 seeds × 600 runs is infeasible with wet-lab feedback) and are standard proxies in the mRNA design literature (MFE/CAI correlate with expression in prior published work, though this EVP does not cite specific validating papers due to unavailable search results). Gap: no wet-lab validation arm is included; ROI estimates assume in-silico gains transfer to real expression, which is unverified here.
  • mediumThe claim of 'dynamic tuning' could trivially collapse to the LLM learning/reproducing a fixed good schedule from its training data (e.g., recommending standard simulated-annealing-style decay), which is not meaningfully different from a hand-tuned fixed schedule — undermining the 'dynamic, context-aware' novelty claim.
    Not fully resolved by current design; recommend adding a diagnostic analysis correlating LLM-output mutation rates against population state variables (regression/mutual information) to confirm genuine state-dependence versus a constant/decay-only pattern — this analysis is not yet in the protocol and should be added before claiming 'dynamic tuning' is demonstrated.

Experimental Protocol

Minimum viable test (MVT): 5 benchmark mRNA design tasks (2 synthetic ViennaRNA-based structure-minimization tasks, 2 real therapeutic targets — e.g., SARS-CoV-2 spike RBD-coding mRNA and EPO mRNA — with CAI+MFE joint objective, 1 adversarial multimodal landscape task), each run with n=30 random seeds, comparing 4 arms: (1) fixed mutation rate GA, (2) 1/5-success-rule adaptive GA, (3) CMA-ES self-adaptive, (4) LLM-scheduled GA (GPT-4o-mini or Llama-3.1-8B-Instruct as controller, called every 5 generations with summarized population state). Fixed compute budget = 2,000 fitness evaluations per run. Primary endpoints: best fitness at budget exhaustion, generations-to-90%-of-best-known-fitness, wall-clock time, total dollar cost including LLM API calls.

Required datasets:
  • Benchmark sequence set: 10–20 real therapeutic mRNA CDS/UTR sequences from NCBI RefSeq / literature (e.g., EPO, spike RBD, luciferase reporter — used as design targets, not training data).
  • Fitness oracles: ViennaRNA 2.6 (MFE/structure), LinearFold (fast MFE approximation for long sequences), CAI calculator (codon usage tables from Kazusa/HIVE-CUT for human), and optionally a pretrained mRNA stability/translation-efficiency surrogate model (e.g., Optimus 5-Prime, CodonBERT, or an in-house regression model if available) as a secondary fitness signal.
  • LLM controllers: GPT-4o-mini (API), Llama-3.1-8B-Instruct and Llama-3.1-70B-Instruct (self-hosted, for cost/ablation control), plus one open-weight reasoning-tuned model (e.g., Qwen2.5-32B-Instruct) for robustness check.
  • Classical baselines: DEAP or custom GA implementation with 1/5-rule, CMA-ES (pycma library).
  • Compute environment: single-node 4×A100-80GB (for local LLM inference + parallelized GA runs), plus API budget for closed-model comparisons.
  • No dependency on the MS transcriptomics datasets (GSE193770, GSE138614, GTEx, STRING) — these are unrelated to this discovery and are noted only because they appear in the shared context.
Success:
  • Primary: LLM-scheduled GA beats best classical adaptive baseline (CMA-ES or 1/5-rule) by ≥10% in final normalized fitness OR ≥30% fewer generations-to-90%-best-known-fitness, significant at p<0.05 (Holm-corrected) on ≥4 of 5 tasks.
  • Secondary: Ablation A shows LLM controller outperforms linear-bandit controller by ≥5% (establishes LLM-specific value, not just "any adaptive controller").
  • Cost-normalized efficiency of LLM arm is within 2× of best classical baseline (i.e., gains aren't erased by API cost) using GPT-4o-mini pricing.
  • Held-out generalization: performance advantage retained (≥5% improvement) on ≥3 of 5 held-out targets.
Failure:
  • No significant difference vs. best classical baseline on ≥3 of 5 tasks (p≥0.05 after correction).
  • LLM arm matched or beaten by linear-bandit ablation on ≥3 of 5 tasks → conclude effect is "adaptive control," not "LLM-specific."
  • Cost-normalized efficiency of LLM arm >5× worse than classical baseline (API cost dominates any fitness gain) → conclude impractical at current LLM pricing/latency.
  • Held-out generalization fails (gains vanish or reverse on new targets) → conclude prompt/schedule overfit to benchmark tasks.
  • LLM outputs invalid/unstable schedules (>10% of calls fail JSON validation or produce degenerate rates causing GA divergence) without robust fallback.

ROI Projection

Implementation Sketch

for generation in range(max_generations):
    state = summarize_population(population)  # mean/var/best/worst fitness,
                                                 # diversity, stagnation_count
    if generation % k == 0:
        prompt = build_prompt(state, task_description, history[-5:])
        response = llm.query(prompt, schema=MutationScheduleSchema)
        mutation_rate = clip(response.mutation_rate, 1e-4, 0.5)
        crossover_rate = clip(response.crossover_rate, 0.0, 1.0)
        log(generation, state, mutation_rate, crossover_rate)
    offspring = crossover(population, crossover_rate)
    offspring = mutate(offspring, mutation_rate)
    fitness = evaluate(offspring, oracle=[ViennaRNA_MFE, CAI, surrogate])
    population = select(population + offspring, fitness)
    if converged(population, tol) or eval_budget_exhausted():
        break
record_metrics(best_fitness, generations_used, wallclock, api_cost)

Ablation swap point: replace llm.query(...) with bandit_controller.predict(state) (linear/logistic model trained online via Thompson sampling) for Ablation A.

Abort checkpoints:
  • Day 7 (after baseline + LLM arm on 1 task, n=10 seeds): if LLM arm shows no directional trend (mean improvement <2%) vs. CMA-ES, halt and reassess prompt design before scaling to full n=30×5 tasks.
  • Day 15 (after Ablation A, linear-bandit control): if bandit matches LLM performance within 3%, deprioritize full LLM-cost scale-up; pivot framing to "adaptive control" rather than "LLM-specific" claim.
  • Day 25 (after full 600-run sweep): if Holm-corrected significance not reached on ≥4/5 tasks, do not proceed to held-out generalization phase — report negative/mixed result.

NAMED_EXPERTS: []

CLOSEST_EXISTING_WORK: []

NOVELTY_NARROWING_REQUIRED: true

SPINE_STATEMENT: This hypothesis tests whether an LLM-driven meta-controller that dynamically sets mutation rates during evolutionary mRNA sequence design produces significantly better fitness outcomes per unit compute than classical adaptive (non-LLM) mutation-rate schedules.

Source

AegisMind Research
Need AI to work rigorously on your problems? AegisMind uses the same multi-model engine for personal and professional use. Get started